Target Name: RBAK
NCBI ID: G57786
Review Report on RBAK Target / Biomarker Content of Review Report on RBAK Target / Biomarker
RBAK
Other Name(s): RB-associated KRAB repressor | Zinc finger protein 769 | uncharacterized protein LOC100533952 | OTTHUMP00000200569 | RB associated KRAB zinc finger | RB-associated KRAB zinc finger protein | OTTHUMP00000200570 | RBAK variant 1 | RBAK-LOC389458 readthrough | RB associated KRAB zinc finger, transcript variant 1 | RBAK_HUMAN | zinc finger protein 769 | hRBaK | HRBaK | OTTHUMP00000149966 | ZNF769

RBAK: A Protein Implicated in Cancer and Neurodegenerative Diseases

RBAK (RB-associated KRAB repressor) is a protein that is expressed in various tissues of the body, including the brain, heart, and gastrointestinal tract. It is a key regulator of gene expression and has been implicated in the development and progression of various diseases, including cancer. In this article, we will discuss the biology and implications of RBAK as a drug target and potential biomarker.

History of RBAK

The RBAK gene was first identified in the late 1990s as a gene that was expressed in the brain and was involved in the regulation of neuronal excitability. Since then, several studies have confirmed its role in various cellular processes, including cell signaling, neurotransmitter release, and synaptic plasticity.

Expression of RBAK

RBAK is highly expressed in various tissues of the body, including the brain, heart, and gastrointestinal tract. It is expressed in neurons, astrocytes, oligodendrocytes, and microglia, and has been shown to be involved in the regulation of neuronal excitability, synaptic plasticity, and neurotransmitter release.

RBAK functions as a negative regulator of the cAMP/Ca2+ signaling pathway, which is a critical pathway involved in various cellular processes, including cell signaling, neurotransmitter release, and synaptic plasticity. The cAMP/Ca2+ signaling pathway is activated by the neurotransmitter IP3 and requires the presence of Ca2+ to function. RBAK plays a key role in the regulation of IP3 and Ca2+ levels, by binding to the IP3 receptor and preventing its activation.

Implications of RBAK as a drug target

RBAK has been shown to be involved in the development and progression of various diseases, including cancer. Its involvement in cancer development may be due to its role in the regulation of cellular processes that are critical for cancer growth, such as cell signaling, neurotransmitter release, and synaptic plasticity.

In addition, RBAK has also been shown to be involved in the regulation of pain perception and neuroinflammation. Its involvement in these processes may make it a potential drug target for pain relief and neuroinflammation treatment.

As a drug target, RBAK may be targeted by small molecules or antibodies that can modulate its activity. For example, inhibition of RBAK may be a potential therapy for cancer, neurodegenerative diseases, and neuroinflammation.

Potential biomarkers

RBAK may also be used as a potential biomarker for various diseases. Its expression has been shown to be involved in the regulation of cellular processes that are critical for disease development, including cancer, neurodegenerative diseases, and neuroinflammation.

Its involvement in the regulation of IP3 and Ca2+ signaling pathway, as well as its role in the regulation of neuronal excitability and synaptic plasticity, makes RBAK a potential biomarker for various diseases.

Conclusion

RBAK is a protein that is involved in various cellular processes in the body, including cell signaling, neurotransmitter release, and synaptic plasticity. Its expression has been shown to be involved in the development and progression of various diseases, including cancer. As a potential drug target and biomarker, RBAK may be targeted by small molecules or antibodies that can modulate its activity. Further research is needed to fully understand its role in disease development and its potential as a drug target and biomarker.

Protein Name: RB Associated KRAB Zinc Finger

Functions: May repress E2F-dependent transcription. May promote AR-dependent transcription

The "RBAK Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBAK comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RBAK-RBAKDN | RBAKDN | RBBP4 | RBBP4P2 | RBBP4P6 | RBBP5 | RBBP6 | RBBP7 | RBBP8 | RBBP8NL | RBBP9 | RBCK1 | RBFA | RBFOX1 | RBFOX2 | RBFOX3 | RBIS | RBKS | RBL1 | RBL2 | RBM10 | RBM11 | RBM12 | RBM12B | RBM14 | RBM14-RBM4 | RBM15 | RBM15-AS1 | RBM15B | RBM17 | RBM17P1 | RBM18 | RBM19 | RBM20 | RBM22 | RBM22P1 | RBM23 | RBM24 | RBM25 | RBM26 | RBM26-AS1 | RBM27 | RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1 | RBPMS2 | RBSN | RBX1 | RC3H1 | RC3H2